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Guidelines for choosing drugs in chronic heart failure
In a recent article, Komajda and colleagues (2005) presented data gathered from the
Medical Management of Chronic Heart Failure in Europe and its Related Costs
(MAHLER) survey in support of the view that adherence to guidelines in treating
patients with chronic heart failure is a strong predictor of fewer cardiovascular
hospitalizations in clinical practice.
Five types of drugs were considered as the agents of choice in the treatment of
chronic heart failure: angiotensin-converting enzyme (ACE) inhibitors,
β-adrenoceptor antagonists (blockers), potassium sparing diuretic (spironolactone),
cardiac glycosides, and diuretics other than the potassium-sparing class. The total
number of patients included in the trial were 1421, of whom 1333 (93.8%) completed
the study. Baseline medications in these patients were ACE inhibitors (69%),
angiotensin type 1 receptor antagonists (17.6%), β-adrenoceptor antagonists (53%),
diuretics (79%), cardiac glycosides (41%), and spironolactone (28%). Adherence
was considered perfect if the first three (T3) drugs (ACE inhibitor, β-adrenoceptor
antagonist, and spironolactone) were used, and this was compared with a situation
when either the latter three were not used concomitantly or a condition in which all
five (T5) were used as part of the regime to treat chronic heart failure. The overall
guideline adherence indicators for T3 and T5 were 60% and 63%, respectively, with
class adherence for ACE inhibitors (85.4%), diuretics (83%), β-adrenoceptor
antagonists (58%), cardiac glycosides (52%), and spironolactone (36%) (Komajda
et al 2005). Of particular interest, are two issues that are worth addressing based on
the findings from the Komajda et al report.
First, the data presented supports the view that β-adrenoceptor antagonists are
underutilized in the treatment of patients with chronic heart failure. This is somewhat
surprising as there is substantive evidence to indicate that this class of drugs should
form an integral part of a strategy in treating patients with this condition. A previous
survey on the quality of care among patients with heart failure in Europe had also
revealed an underutilization of β-adrenoceptor antagonists in these patients (The
Study Group of Diagnosis of the Working Group on Heart Failure of the European
Society of Cardiology 2003). The evidence from this report seems to indicate that
the rate of prescription for β-adrenoceptor antagonists was 36.9%, with metoprolol
being the most widely used (40.3%) agent among the β-adrenoceptor antagonists.
There is clear evidence from a number of clinical trials that indicate the benefits of
β-adrenoceptor antagonists in patients with left systolic dysfunction (Packer et al
1996, 2001; CIBIS-II Investigation and Committee 1999; MERIT-HF Study Group
1999). As well, post-hoc analysis of the data from Metoprolol Randomized
Intervention Trial in Congestive Heart Failure on many levels, ie, frequency of
hospitalization, quality of life, and functional class, indicate the clear beneficial effects
of this class of drugs in treating patients with chronic heart failure (Hjalmarson et al
2000; Goldstein et al 2001; Ghali et al 2002; Gottlib et al 2002; Wikstrand et al
2002). The use of this class of drugs reduces hospitalization due to worsening heart
failure, increases life expectancy, and reduces all-cause hospitalization (Tabrizchi
2003). Thus, perhaps a greater effort should be made to encourage the appropriate
use of this class of drugs in patients with chronic heart failure.Vascular Health and Risk Management 2005:1(3) 172
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Second, the trend was that the group of patients taking
the three drugs, ie, ACE inhibitor, β-adrenoceptor antagonist,
and spironolactone (T3), were more likely to experience
hospitalization due to cardiovascular problems when
compared with those taking the five drugs (T5). This off-
hand observation, if real, clearly needs closer examination.
Perhaps not surprisingly, a relatively simple hypothesis to
explain this observation would be on the basis of the
pharmacological actions of the three agents employed. The
simple explanation would be an unwanted elevation of serum
potassium levels resulting in higher incidence of
cardiovascular problems. It is interesting that following the
publication of the Randomized Aldactone Evaluation Study
(RALES; The RALES Investigators 1996) there was an
increase in the use of spironolactone. The concomitant use
of spironolactone and ACE inhibitors in patients with heart
failure was stable in the period of early 1994 until early
1999 (~34 per 1000 patients) (Juurlink et al 2004). However,
subsequent to the publication of RALES, the rate of
prescription increased significantly (p < 0.001) by a factor
of approximately fivefold (149 per 1000) by late 2001. Of
interest was the rate of hospital admission associated with
hyperkalemia, which was 2.4 per 1000 in early 1994 and
4.0 per 1000 in early 1999, and that rate increased further
after the publication of RALES to 11.0 per 1000 (p < 0.001)
by late 2001 (Juurlink et al 2004). The use of ACE inhibitor
and spironolactone together has the potential to create a
greater risk of the serum potassium becoming elevated in
patients with heart failure as does the use of a β-adrenoceptor
antagonist (Swenson 1986; Hamad et al 2001; Tamirisa et
al 2004).
Therefore, it should not be a surprise that the
combination of the three would provide a clinical situation
that could predispose the patient to a greater risk of
manifesting an elevated level of serum potassium. Moreover,
one reason that the five drug combination may not produce
the same outcome is because of the fact that drugs such as
thiazides and loop diuretics cause some degree of serum
potassium depletion by the virtue of their pharmacological
effects in the nephron. This action may prevent the rise in
serum potassium to levels that precipitate the cardiovascular
problems exhibited by the patients on the T3 drugs.
This hypothesis, of course, can easily be tested by
examining electrolyte records of patients on these drugs
admitted for cardiovascular problems. However, more
importantly, the medical community must be made aware
of the risk associated with this form of drug interaction and
implement appropriate guidelines to prevent its occurrence
in this patient population.
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